Propel Bio Management »

Trevi Therapeutics shares owned by Propel Bio Management

Quarter-by-quarter ownership of Trevi Therapeutics (TRVI) shares owned by Propel Bio Management from 13F filings

Historical chart of Propel Bio Management investment in Trevi Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Trevi Therapeutics held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Trevi Therapeutics by Propel Bio Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $897k 260k 3.45

More positions owned by Propel Bio Management

Applied Therapeutics Comm (APLT)
Plains Gp Holdings Lp-cl Comm (HIGH)
Tscan Therapeutics Comm (TCRX)
Madrigal Pharmaceuticals Comm (MDGL)
Achieve Life Sciences Comm (ACHV)
Phathom Pharmaceuticals Comm (PHAT)
Akero Therapeutics Comm (AKRO)
Fulcrum Therapeutics Comm (FULC)
Avidity Biosciences Comm (RNA)
Day One Biopharmaceuticals I Comm (DAWN)
Ardelyx Comm (ARDX)
Athira Pharma Comm (ATHA)
Kura Oncology Comm (KURA)
Telesat Corp Comm (TSAT)
Kymera Therapeutics Comm (KYMR)

View all positions for Propel Bio Management

Top funds holding Trevi Therapeutics

NEA Management Company
Frazier Life Sciences Management
Rubric Capital Management
Viking Global Investors
VR Adviser
Opaleye Management
BlackRock
Vanguard Group
Logos Global Management
MPM Oncology Impact Management
MAI Wealth Advisors
Rosalind Advisors
Geode Capital Management
Landscape Capital Management
Checkpoint Capital

View all funds holding Trevi Therapeutics